<mods:mods xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" version="3.3" xmlns:mods="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><mods:titleInfo><mods:title>POLYCYSTIC OVARIAN SYNDROME AND MENOPAUSE</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Nomurodova Shahnoza</mods:namePart><mods:namePart type="family">Gaffarovna</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Hamidova Manzura</mods:namePart><mods:namePart type="family">Sattarovna</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Imamov Elmurod</mods:namePart><mods:namePart type="family">Norkuchkarovich</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies, which occurs in 4–21% of women during reproductive age and is the most common form of hyperandrogenism [1, 2]. The clinical manifestations of PCOS are diverse, and most of them accompany a woman throughout her life, varying depending on age, ethnicity, constitutional and other factors. Due to the increase in average life expectancy, modern women spend quite a long period in peri- and postmenopause, which determines the need to monitor the clinical manifestations of PCOS, its long-term complications, as well as the features of the onset and course of age-associated diseases in this endocrinopathy [3–6].</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2023-12-17</mods:dateIssued></mods:originInfo><mods:originInfo><mods:publisher>"Research Science and Innovation house" LLC</mods:publisher></mods:originInfo><mods:genre>Maqola</mods:genre></mods:mods>